Searched for
ONCOLOGY DRUGS
$10. 6 billion deal: GSK to buy US cancer specialist NuvalentBritish pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in c...- Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapseThe US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion...
- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- Hospital expansion cycle to keep margins rangebound, but 18 per cent revenue growth trend likely to sustain: Kotak SecuritiesIndian hospitals are set for strong revenue growth. Brokerage firm Kotak Securities predicts double-digit gains. EBITDA margins are expecte...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
- Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage studyThe study, which followed patients for over five years, found that those who received the regimen were nine times more likely to have lit...
- Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...
- Could space-grown stem cells unlock faster cancer treatments and revolutionize organ regeneration breakthroughs? NASA’s ISS experiments are revealing surprising answers about the power of microgravity medicineSpace stem cell research is rapidly changing cancer treatment and regenerative medicine worldwide. Scientists aboard the International Spac...
- Sakar Healthcare partners with Zydus Lifesciences for GCC MarketsSakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Venus Remedies gets Saudi FDA approval for speciality oncology therapyVenus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi ...
- Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...
- Cenexi recovery, new product launches and capacity additions power Gland Pharma outlookGland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- Roche brings 7-minute lung cancer shot to IndiaRoche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduct...
- Roche Pharma launches India’s first 7-minute injectable immunotherapy for lung cancerRoche Pharma has introduced Tecentriq, India's first under-the-skin immunotherapy for lung cancer. This new injection takes about seven min...
- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: SourcesIndian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acqu...
Load More
